Sperm-hybrid micromotor for drug delivery in the female reproductive
  tract

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

A sperm-driven micromotor is presented as cargo-delivery system for the treatment of gynecological cancers. This particular hybrid micromotor is appealing to treat diseases in the female reproductive tract, the physiological environment that sperm cells are naturally adapted to swim in. Here, the single sperm cell serves as an active drug carrier and as driving force, taking advantage of its swimming capability, while a laser-printed microstructure coated with a nanometric layer of iron is used to guide and release the sperm in the desired area by an external magnet and structurally imposed mechanical actuation, respectively. The printed tubular microstructure features four arms which release the drug-loaded sperm cell in situ when they bend upon pushing against a tumor spheroid, resulting in the drug delivery, which occurs when the sperm squeezes through the cancer cells and fuses with cell membrane. Sperms also offer higher drug encapsulation capability and carrying stability compared to other nano and microcarriers, minimizing toxic effects and unwanted drug accumulation. Moreover, sperms neither express pathogenic proteins nor proliferate to form undesirable colonies, unlike other cells or microorganisms do, making this bio-hybrid system a unique and biocompatible cargo delivery platform for various biomedical applications, especially in gynecological healthcare.

Related collections

Most cited references 7

Record: found
Abstract: found
Article: not found

Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Phatsapong Yingchoncharoen, Danuta S Kalinowski, Des R. Richardson … (2016)

Cancer is a leading cause of death in many countries around the world. However, the efficacy of current standard treatments for a variety of cancers is suboptimal. First, most cancer treatments lack specificity, meaning that these treatments affect both cancer cells and their normal counterparts. Second, many anticancer agents are highly toxic, and thus, limit their use in treatment. Third, a number of cytotoxic chemotherapeutics are highly hydrophobic, which limits their utility in cancer therapy. Finally, many chemotherapeutic agents exhibit short half-lives that curtail their efficacy. As a result of these deficiencies, many current treatments lead to side effects, noncompliance, and patient inconvenience due to difficulties in administration. However, the application of nanotechnology has led to the development of effective nanosized drug delivery systems known commonly as nanoparticles. Among these delivery systems, lipid-based nanoparticles, particularly liposomes, have shown to be quite effective at exhibiting the ability to: 1) improve the selectivity of cancer chemotherapeutic agents; 2) lower the cytotoxicity of anticancer drugs to normal tissues, and thus, reduce their toxic side effects; 3) increase the solubility of hydrophobic drugs; and 4) offer a prolonged and controlled release of agents. This review will discuss the current state of lipid-based nanoparticle research, including the development of liposomes for cancer therapy, different strategies for tumor targeting, liposomal formulation of various anticancer drugs that are commercially available, recent progress in liposome technology for the treatment of cancer, and the next generation of lipid-based nanoparticles.

0 comments Cited 187 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Cell or Cell Membrane-Based Drug Delivery Systems

Songwei Tan, Tingting Wu, Dan-Dan Zhang … (2015)

Natural cells have been explored as drug carriers for a long period. They have received growing interest as a promising drug delivery system (DDS) until recently along with the development of biology and medical science. The synthetic materials, either organic or inorganic, are found to be with more or less immunogenicity and/or toxicity. The cells and extracellular vesicles (EVs), are endogenous and thought to be much safer and friendlier. Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS. In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles. We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.